Module 8: Questions on Management and Treatment: Side Effects and Drug Interactions
This learning activity has been designated for 1.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
After completing this educational activity, the learner should be better able to:
- Explain the importance of treating patients with chronic myeloid leukemia (CML) experiencing a suboptimal response to treatment according to the accepted guidelines
- Assess response to treatment in patients with CML
- Identify patients with CML who are not responding optimally to treatment
- Formulate an alternative treatment plan for patients whose first-line therapy has failed or who have had a suboptimal response to first-line therapy
This learning activity is intended for medical oncologists, hematologists, stem cell transplant physicians, and other interested healthcare professionals who manage and treat chronic myelogenous leukemia in the hematology/oncology and transplant patient settings.
Release Date: November 30, 2008
Expiration date: November 30, 2009
(*Please check this box to proceed - required)
Start the Module